Double dose influenza vaccination may not improve cardiopulmonary outcomes in acute coronary syndrome

Written By : Jacinthlyn Sylvia |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-09-19T20:00:12+05:30 | Updated On 14 Feb 2024 12:27 PM IST

Brazil: A new study conducted by Henrique Andrade R Fonseca and his team showed that receiving two doses of the influenza vaccine before discharge did not improve cardiopulmonary outcomes when compared to outpatient standard-dose immunization in patients with acute coronary syndrome (ACS). The findings of this study were published in European Heart Journal.

The Vaccination against Influenza to Prevent Cardiovascular Events after Acute Coronary Syndromes (VIP-ACS) trial compared two influenza vaccination strategies after an ACS: double-dose quadrivalent inactivated vaccine is given before hospital discharge vs. standard-dose quadrivalent inactivated vaccine given in the outpatient setting 30 days after randomization. It was a randomized, multicenter, open-label trial with blinded outcome adjudication. The main result, which was evaluated using the win ratio approach, was a hierarchical composite of all-cause mortality, myocardial infarction, stroke, unstable angina, hospitalization for heart failure, urgent coronary revascularization, and hospitalization for respiratory reasons.

The key findings of this study were:

1. At 25 Brazilian locations throughout the course of two influenza seasons, 1801 participants were registered.

2. With 12.7% victories in the in-hospital double-dose vaccination group and 12.3% victories in the standard-dose vaccine group, the main result did not vary across the groups.

3. The major secondary outcome, a hierarchical composite of cardiovascular mortality, myocardial infarction, and stroke, showed consistent results.

4. The results of the time-to-first event analysis for the primary outcome matched those of the main analysis. Adverse outcomes were uncommon and did not vary by group.

In conclusion, when compared to outpatient standard-dose immunization among patients hospitalized with ACS in the VIP-ACS study, a double-dose quadrivalent influenza vaccine did not enhance cardiopulmonary outcomes.

Source:

Fonseca, H. A. R., Furtado, R. H. M., Zimerman, A., Lemos, P. A., Franken, M., Monfardini, F., Pedrosa, R. P., Patriota, R. de L. S., Passos, L. C. S., Dall'Orto, F. T. C., Hoffmann Filho, C. R., Esteves, C., Salim, E. F., da Silva, J. H., … Berwanger, O. (2022). Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial. In European Heart Journal. Oxford University Press (OUP). https://doi.org/10.1093/eurheartj/ehac472

Influenza vaccinationEuropean Heart Journalacute coronary syndrome

Source : European Heart Journal

Jacinthlyn Sylvia

Neuroscience Masters graduate

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751